The efficacy of tolvaptan in a population with congestive heart failure and chronic kidney disease: A multicenter, randomized, open label, blind endpoint study (AQUAKID-Study)
- Conditions
- congestive heart failure and chronic kidney disease
- Registration Number
- JPRN-UMIN000012006
- Lead Sponsor
- Fujita Health University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Not provided
1.Patients who recently started undergoing hemodialysis 2.Patients treated with the following drugs during the initial eligibility assessment period (a)Phosphodiesterase III inhibitors (amrinone, milinone, or loprinone) (b)Catecholamines (c)Colforsins 3.Acute renal failure 4.Hypernatremia, Na levels ≥147 mEq/dL 5.Patients unable to sense thirst or those with difficulty drinking water 6.Anuria 7.Patients with malignancy, including multiple myeloma or primary amyloidosis 8.Patients suspected of having loss of circulating plasma volume or patients with hypotension 9.Severe aortic stenosis or severe dilated cardiomyopathy 10.Acute coronary syndrome 11.Recent myocardial infarction, percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG) within the past 3 months 12.Patients scheduled for PCI or CABG 13.Stroke within the past 3 months 14.Severe neuropsychological deficit 15.Severe liver damage or hepatic coma 16.Severe obstructive and/or restrictive lung disease 17.Severe pulmonary hypertension 18.Patients with other life-threatening illnesses 19.Pregnant women 20.Allergy to tolvaptan 21.Others deemed ineligible for this trial by physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method